Xbrane Biopharma AB (publ) reported earnings results for the full year ended December 31, 2023. For the full year, the company reported sales was SEK 238.73 million compared to SEK 57.62 million a year ago. Net loss was SEK 388.17 million compared to SEK 172.51 million a year ago.

Basic loss per share from continuing operations was SEK 11.22 compared to SEK 6.59 a year ago. Diluted loss per share from continuing operations was SEK 11.22 compared to SEK 6.59 a year ago. Basic loss per share was SEK 13.52 compared to SEK 6.75 a year ago.

Diluted loss per share was SEK 13.52 compared to SEK 6.75 a year ago.